The devil will be in the detail of the retts trial as well on...

The devil will be in the detail of the retts trial as well on this. One interesting thing will be what the fda allows for fragile x future trials. The retts trial to me was almost a fx pseudo trial in terms of dosing and safety information and I’m hoping the fda looks at it the same way. At the end of the day the primary reason for p2 is safety (with signs of efficacy). Neu p2a fragile x trial did show efficacy signals so I’m hoping the fda allows some sort of pivotal p2b/3 trial

Be interesting to see if the fda allows retts data to be used in fx also in terms of professing it . Cautiously optimistic on that

I think the whole story and path forward will unravel soon , after all they need to keep the wheels turning to get it to market asap